Table 2_High-dose accelerated intermittent theta burst stimulation targeting the primary m

Xiao-Ying Zhao published clinical trial data on figshare in 2026. The dataset contains results from a randomized, single-blind, sham-controlled study of high-dose accelerated intermittent theta burst stimulation (aiTBS) targeting the primary motor cortex in 36 patients with cerebral small vessel disease (CSVD). It includes primary and secondary outcome measures for gait and cognitive function assessed at baseline, post-intervention, and a 4-week follow-up.

Use Cases

• Evaluate the efficacy of a non-invasive brain stimulation protocol based on primary outcome measures like the 3-meter Timed Up and Go test.
• Analyze the correlation between neuroimaging phenotypes and treatment response based on features like periventricular white matter hyperintensity and total CSVD burden score.
• Compare multidimensional functional outcomes between intervention and control groups based on secondary measures like the Tinetti Assessment, Mini-Mental State Examination, and Montreal Cognitive Assessment scores.
• Model longitudinal treatment effects on gait and cognitive symptoms based on data collected at three time points (baseline, post-intervention, and 4-week follow-up).

Strengths

• Data originates from a randomized controlled trial with a sham-control group (n=19 real, n=17 sham), a key methodological strength.
• Includes longitudinal measurements at three time points (baseline, post-intervention, and 4-week follow-up).
• Assesses multiple domains of function, including gait, cognition, affect, and autonomic nervous function.

Limitations

• The dataset is very small at 17.2 KB, indicating limited scope and a small sample size of 36 patients.
• Column-level documentation is absent; field semantics must be inferred from the description after download.
• Row count is unknown, which may limit suitability assessment for certain analyses.

Provenance

Source

Xiao-Ying Zhao

Collection Method

Data collected as part of a randomized, single-blind, sham-controlled clinical trial.

Freshness

Last updated 2026-06-01 05:24:46